Wang Eric M, Akasaka Hironari, Zhao Jun, Varadhachary Gauri R, Lee Jeffrey E, Maitra Anirban, Fleming Jason B, Hung Mien-Chie, Wang Huamin, Katz Matthew H G
Anatomic Pathology.
Gastrointestinal Medical Oncology.
Pancreas. 2019 Mar;48(3):323-328. doi: 10.1097/MPA.0000000000001248.
Endoplasmic reticulum stress and subsequent phosphorylation of eukaryotic initiation factor 2α (eIF2α) by protein kinase R-like endoplasmic reticulum kinase (PERK) plays an important role in the development and chemoresistance of pancreatic ductal adenocarcinoma (PDAC). However, the expression and significance of phosphorylated eIF2α (p-eIF2α) and PERK in PDAC have not been examined.
We examined p-eIF2α and PERK expression in 84 PDAC and paired normal pancreas samples by immunohistochemistry and Western blotting and correlated the results with clinicopathologic parameters and survival.
Mean PERK H score was 140.8 in PDAC compared with 82.1 in normal pancreas (P < 0.001). High p-eIF2α expression was present in 56% of PDACs versus 7.6% of normal pancreases (P < 0.001). High PERK and p-eIF2α expression correlated with shorter overall survival (P = 0.048 and P = 0.03, respectively). By multivariate analysis, high p-eIF2α (P = 0.01), positive margin (P = 0.002), and lymph node metastasis (P = 0.01) were independent prognosticators for survival.
The expression levels of PERK and p-eIF2α are higher in PDAC than those in normal pancreas. High levels of PERK and p-eIF2α are predictors of shorter survival in PDAC patients, suggesting that PERK and eIF2α could be promising targets in PDAC.
内质网应激以及随后蛋白激酶R样内质网激酶(PERK)对真核起始因子2α(eIF2α)的磷酸化在胰腺导管腺癌(PDAC)的发生发展及化疗耐药中起重要作用。然而,磷酸化eIF2α(p-eIF2α)和PERK在PDAC中的表达及意义尚未得到研究。
我们通过免疫组织化学和蛋白质印迹法检测了84例PDAC及其配对的正常胰腺组织样本中p-eIF2α和PERK的表达,并将结果与临床病理参数及生存情况进行关联分析。
PDAC中PERK的平均H评分为140.8,而正常胰腺中为82.1(P<0.001)。56%的PDAC中存在高p-eIF2α表达,而正常胰腺中这一比例为7.6%(P<0.001)。高PERK和p-eIF2α表达与较短的总生存期相关(分别为P=0.048和P=0.03)。多因素分析显示,高p-eIF2α(P=0.01)、切缘阳性(P=0.002)和淋巴结转移(P=0.01)是生存的独立预后因素。
PDAC中PERK和p-eIF2α的表达水平高于正常胰腺。高水平的PERK和p-eIF2α是PDAC患者生存期较短的预测指标,提示PERK和eIF2α可能是PDAC中有前景的治疗靶点。